Lizzie DeLacy, founder of DeLacy Wellness, launched a new platform called Bodypeace offering wellness and exercise tips through the app. Courtesy of DeLacy Wellness

As time spent on mobile devices stretches longer and attention spans get shorter, a Houstonian thinks she has a solution to combine personal technology and a healthy lifestyle.

Lizzie DeLacy, founder of DeLacy Wellness, has launched a new app called Bodypeace that offers workout sessions, recipes, and tips for a healthier lifestyle, but in a different way than consumers might be used to.

"Rather than focusing on really long sessions, though we have a couple in there, we focus on short 5 minute sessions, so anyone can fit movement into their schedule and lifestyle," DeLacy tells InnovationMap. "Additionally, we break it down by body part focus, because oftentimes people don't know necessarily what exact movement or pose or stretch they might need."

DeLacy worked as a private fitness instructor for years before deciding to create the Bodypeace app to make her coaching and practices accessible to more people. Her goal is to help as many people as possible feel better so they can grow to be the best version of themselves, referring to this concept as "Eventual Energy."

The Bodypeace app, which launched on iTunes and Google Play on July 17, allows users to filter by body part, choosing between an all body session, or focus on a specific spot such as hamstrings, hips, back, shoulders, and more.

"In my experience as a yoga instructor, I saw that these are pain points for a lot of people," says DeLacy.

The app tailors content for the user by asking a series of questions about workout habits, and lifestyle. There is a free trial period for users to explore the app, as well as paid options, $17.99 a month or $119.99 a year.

"The busier people get the less they want to spend time in their cars or pay the fees that are associated with gym memberships, and having the ability to do something from the comfort of your own home or on demand that fits your schedule," says DeLacy. "I think it's really appealing to a lot of people, myself included."

DeLacy shares that many fitness apps out there geared towards getting a six pack or losing weight can be intimidating to those that have never worked out before or have an injury that they're recovering from. She designed her app to be accessible for all fitness levels, ages, and genders.

"The content on Bodypeace is really for the athletes and the 'never-evers' alike," DeLacy tells InnovationMap. "There is a whole group of people that are either new to working out or have never considered it before."

DeLacy founded DeLacy Wellness in 2016, a year after she moved to Houston. DeLacy is a certified yoga instructor and holds a health coaching certification. The company, which is privately funded, has two full-time staff, DeLacy and her partner and COO Jack Martin, two advisory board members, two instructors, and one community contributor.

DeLacy tells InnovationMap that on the community portion of the Bodypeace app, there is a lot of free information available for users to test the content. DeLacy and her team hope to connect wellness content creators and contributors with people who are looking for information to feel and live better.

"We're hoping to create a platform where you're doing movement and you're also going to learn about movement, nutrition, mental health, and other topics dealing with wellness," says DeLacy.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”